Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients

Samih H Nasr, Surendra Dasari, John C. Lieske, Linda M. Benson, Patrick M. Vanderboom, Carrie J. Holtz-Heppelmann, Callen D. Giesen, Melissa R. Snyder, Stephen B. Erickson, Fernando C. Fervenza, Nelson Leung, Paul J. Kurtin, Mariam P. Alexander

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. Kidney biopsy is required to establish the diagnosis. Recent studies have identified abundant glomerular deposition of DNAJB9 as a unique histological marker of FGN. We developed an immunoprecipitation-based multiple reaction monitoring method to measure serum levels of DNAJB9. We detected a 4-fold higher abundance of serum DNAJB9 in FGN patients when compared to controls, including patients with other glomerular diseases. Serum DNAJB9 levels were also negatively associated with estimated glomerular filtration rate in patients with FGN. Serum DNAJB9 levels accurately predicted FGN with moderate sensitivity (67%) and with high specificity (98%) and positive and negative predictive value (89% and 95%, respectively). A receiver operating curve analysis demonstrated an AUC of 0.958. These results suggest that serum levels of DNAJB9 could be a valuable marker to predict FGN, with the potential to complement kidney biopsy for the diagnosis of FGN.

Original languageEnglish (US)
Pages (from-to)1269-1272
Number of pages4
JournalKidney international
Issue number5
StatePublished - May 2019


  • DNAJB9
  • biomarker
  • fibrillary glomerulonephritis
  • immuno-MRM
  • proteomics
  • serum

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients'. Together they form a unique fingerprint.

Cite this